Clinical Trials Logo

Pancreatic Neuroendocrine Tumors clinical trials

View clinical trials related to Pancreatic Neuroendocrine Tumors.

Filter by:

NCT ID: NCT01381822 Unknown status - Clinical trials for Gastrointestinal Stromal Tumors

Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors

TH-CR-410
Start date: June 2011
Phase: Phase 1
Study type: Interventional

The primary objectives are: Dose escalation: 1. To determine the MTD and DLT(s) of TH-302 when used in combination with sunitinib. Dose expansion: 1. To make a preliminary assessment of the efficacy of TH-302 in combination with sunitinib as determined by the response rate and the progression-free survival in subjects with advanced RCC treated at the RP2D 2. To assess the safety of TH-302 in combination with sunitinib and determine a recommended Phase 2 dose of the combination. The secondary objectives are: Dose expansion: 1. To make a preliminary assessment of the efficacy of TH-302 in combination with sunitinib as determined by stable disease or better rate, duration of response and overall survival in subjects with advanced RCC treated at the RP2D. The exploratory objective is: 1. To explore the association of serum hypoxia biomarkers with efficacy endpoints.

NCT ID: NCT01121562 Completed - Clinical trials for Pancreatic Neuroendocrine Tumors

Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Start date: July 2010
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the effect of Sunitinib on the clinical benefit response rate.

NCT ID: NCT00947167 Terminated - Neuroblastoma Clinical Trials

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Start date: March 2009
Phase: Phase 2
Study type: Interventional

To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients treated with this strategy consisting of initial therapy with pertuzumab as a single agent and then addition of erlotinib for those who have stable disease or progressive disease at three months (Simon design).